Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Axonics files PMA supplement with FDA for implantable sacral neurostimulator » 16:02
06/24/21
06/24
16:02
06/24/21
16:02
AXNX

Axonics

$65.73 /

+0.88 (+1.36%)

Axonics has filed a…

Axonics has filed a premarket approval supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation implantable neurostimulator. Axonics has designed its new non-rechargeable SNM system to replicate key features of its currently marketed, FDA-approved rechargeable SNM system, which provides patients with clinically significant, durable symptom relief and high levels of satisfaction. Raymond W. Cohen, chief executive officer of Axonics, commented, "Since the company's founding, we have focused on developing best-in-class, patient-centric SNM solutions. Our rechargeable system introduced innovations to the SNM category that clinicians and patients had been requesting for years - longevity in the body, MRI compatibility, a miniaturized implant and a fuss-free patient remote control that is easy for patients to use. Our new non-rechargeable system is similarly groundbreaking - a relatively small and thin INS with an expected life in the body that is more than double the competitor's non-rechargeable device. We are confident that the introduction of our non-rechargeable device will continue to drive market expansion and advance Axonics on its path to SNM market leadership."

ShowHide Related Items >><<
AXNX Axonics
$65.73 /

+0.88 (+1.36%)

AXNX Axonics
$65.73 /

+0.88 (+1.36%)

05/07/21 Piper Sandler
Axonics price target raised to $75 from $70 at Piper Sandler
05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
AXNX Axonics
$65.73 /

+0.88 (+1.36%)

  • 12
    May
Over a week ago
Conference/Events
Axonics management to meet virtually with Truist » 04:55
06/11/21
06/11
04:55
06/11/21
04:55
AXNX

Axonics

$59.91 /

+0.19 (+0.32%)

Virtual Meeting to be…

Virtual Meeting to be held on June 11 hosted by Truist.

ShowHide Related Items >><<
AXNX Axonics
$59.91 /

+0.19 (+0.32%)

AXNX Axonics
$59.91 /

+0.19 (+0.32%)

05/07/21 Piper Sandler
Axonics price target raised to $75 from $70 at Piper Sandler
05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
AXNX Axonics
$59.91 /

+0.19 (+0.32%)

  • 12
    May
Conference/Events
Axonics management to meet virtually with Truist » 13:08
06/04/21
06/04
13:08
06/04/21
13:08
AXNX

Axonics

$57.57 /

+1.54 (+2.75%)

Virtual Meeting to be…

Virtual Meeting to be held on June 11 hosted by Truist.

ShowHide Related Items >><<
AXNX Axonics
$57.57 /

+1.54 (+2.75%)

AXNX Axonics
$57.57 /

+1.54 (+2.75%)

05/07/21 Piper Sandler
Axonics price target raised to $75 from $70 at Piper Sandler
05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
AXNX Axonics
$57.57 /

+1.54 (+2.75%)

  • 12
    May
Over a month ago
Hot Stocks
Axonics receives FDA approval further expanding MRI labeling » 06:03
05/20/21
05/20
06:03
05/20/21
06:03
AXNX

Axonics

$54.16 /

+1.01 (+1.90%)

Axonics has received FDA…

Axonics has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI scans. The FDA previously approved 1.5T and 3.0T MRI conditional labeling for using head and full-body transmit coils for the implantable components of the Axonics r-SNM system.

ShowHide Related Items >><<
AXNX Axonics
$54.16 /

+1.01 (+1.90%)

AXNX Axonics
$54.16 /

+1.01 (+1.90%)

05/07/21 Piper Sandler
Axonics price target raised to $75 from $70 at Piper Sandler
05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
AXNX Axonics
$54.16 /

+1.01 (+1.90%)

  • 12
    May
Hot Stocks
Axonics announces CE Mark approval for implantable sacral neurostimulator » 09:06
05/18/21
05/18
09:06
05/18/21
09:06
AXNX

Axonics

$54.37 /

+0.29 (+0.54%)

Axonics announced…

Axonics announced European CE Mark approval of its second generation Axonics r-SNM implantable neurostimulator and wireless patient remote control with SmartMRI technology. Axonics previously received U.S. Food & Drug Administration approval for this INS and remote control during 2020. This version reduces how frequently a patient needs to recharge their sacral neuromodulation device to just once a month for about one hour. The newly approved remote control simplifies the process by which patients can receive a full-body MRI, avoiding the need for the patient to visit their implanting physician's office. "There has been a significant backlog of pending regulatory submissions in Europe due to Covid-19 and the transition to the new European Union Medical Device Regulation, which will become fully applicable later this month," said Rinda K. Sama, chief operating officer of Axonics. "Despite the delay and investment of Axonics' regulatory resources, we are committed to supporting our customers and delivering a superior therapy experience in all markets worldwide where Axonics has an established presence."

ShowHide Related Items >><<
AXNX Axonics
$54.37 /

+0.29 (+0.54%)

AXNX Axonics
$54.37 /

+0.29 (+0.54%)

05/07/21 Piper Sandler
Axonics price target raised to $75 from $70 at Piper Sandler
05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
AXNX Axonics
$54.37 /

+0.29 (+0.54%)

  • 12
    May
Syndicate
Axonics 3.5M share Spot Secondary priced at $50.00 » 06:07
05/12/21
05/12
06:07
05/12/21
06:07
AXNX

Axonics

$52.81 /

-0.22 (-0.41%)

The deal size was…

The deal size was increased to $175M from $150M and priced at midpoint of $49.00-$51.00 range. BofA, Piper Sandler and SVB Leerink are acting as joint book running managers for the offering.

ShowHide Related Items >><<
AXNX Axonics
$52.81 /

-0.22 (-0.41%)

AXNX Axonics
$52.81 /

-0.22 (-0.41%)

05/07/21 Piper Sandler
Axonics price target raised to $75 from $70 at Piper Sandler
05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
AXNX Axonics
$52.81 /

-0.22 (-0.41%)

  • 12
    May
Syndicate
Axonics announces $150M common stock offering » 16:18
05/11/21
05/11
16:18
05/11/21
16:18
AXNX

Axonics

$52.81 /

-0.22 (-0.41%)

Axonics announced that it…

Axonics announced that it has commenced a proposed public offering of $150M in shares of its common stock. Axonics anticipates using net proceeds from the offering to repay all or a portion of its outstanding indebtedness of $75M, support the commercialization of its products throughout the United States and internationally, to conduct related research and development activities and to fund the technological enhancement of its products, and for working capital and general corporate purposes. BofA Securities, Piper Sandler and SVB Leerink are acting as the joint book-running managers for the proposed offering. Baird, Guggenheim Securities, Needham & Company and Truist Securities are acting as co-managers for the offering.

ShowHide Related Items >><<
AXNX Axonics
$52.81 /

-0.22 (-0.41%)

AXNX Axonics
$52.81 /

-0.22 (-0.41%)

05/07/21 Piper Sandler
Axonics price target raised to $75 from $70 at Piper Sandler
05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
AXNX Axonics
$52.81 /

-0.22 (-0.41%)

Recommendations
Axonics price target raised to $75 from $70 at Piper Sandler » 04:57
05/07/21
05/07
04:57
05/07/21
04:57
AXNX

Axonics

$56.01 /

-0.33 (-0.59%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder raised the firm's price target on Axonics to $75 from $70 and reiterates an Overweight rating on the shares. The outperformance in Q1 was primarily driven by the U.S. sacral neuromodulation business, which rebounded nicely in March, Maeder tells investors in a research note. Further, Axonics noted this momentum continued through April and into early May, adds the analyst.

ShowHide Related Items >><<
AXNX Axonics
$56.01 /

-0.33 (-0.59%)

AXNX Axonics
$56.01 /

-0.33 (-0.59%)

05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
03/03/21 Piper Sandler
Piper 'increasingly bullish' on Axonics after closer look at deal
AXNX Axonics
$56.01 /

-0.33 (-0.59%)

  • 08
    May
Earnings
Axonics sees FY21 revenue $176M-$180M, consensus $169.92M  16:03
05/06/21
05/06
16:03
05/06/21
16:03
AXNX

Axonics

$55.45 /

-0.89 (-1.58%)

 
ShowHide Related Items >><<
AXNX Axonics
$55.45 /

-0.89 (-1.58%)

AXNX Axonics
$55.45 /

-0.89 (-1.58%)

05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
03/03/21 Piper Sandler
Piper 'increasingly bullish' on Axonics after closer look at deal
AXNX Axonics
$55.45 /

-0.89 (-1.58%)

  • 08
    May
Earnings
Axonics reports Q1 EPS (57c), consensus (41c) » 16:03
05/06/21
05/06
16:03
05/06/21
16:03
AXNX

Axonics

$55.45 /

-0.89 (-1.58%)

Reports Q1 revenue…

Reports Q1 revenue $34.4M, consensus $27.88M. "This quarter's revenue result reflects growing demand for our long-lived r-SNM(R) system and Bulkamid(R) despite the resurgence of COVID cases in the U.S. in early 2021 and ongoing lockdowns in Europe," said Raymond W. Cohen, CEO of Axonics. "Physician and patient satisfaction remains high and Axonics is poised to take full advantage of the strong growth outlook for sacral neuromodulation as the vaccine rollout continues and we return to a more normalized elective procedure environment."

ShowHide Related Items >><<
AXNX Axonics
$55.45 /

-0.89 (-1.58%)

AXNX Axonics
$55.45 /

-0.89 (-1.58%)

05/03/21 Piper Sandler
Axonics price target raised to $70 from $68 at Piper Sandler
03/24/21 Needham
Axonics price target raised to $71 from $66 at Needham
03/12/21 Piper Sandler
Axonics price target raised to $68 from $64 at Piper Sandler
03/03/21 Piper Sandler
Piper 'increasingly bullish' on Axonics after closer look at deal
AXNX Axonics
$55.45 /

-0.89 (-1.58%)

  • 08
    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.